Health Research, Inc.

Canget Biotek Pharma LLC

The State University of New York

Ganget Biotekpharma, LLC

Fengzhi Li

Xiang Ling

David G Hangauer

Shousong Cao

Jianqun Liao

Taher Hegab

Pasha Apontes

Ali Ghadersohi

Qingyong Li

Described herein, are the extended and newly discovered novel formulations of FL118 for cancer treatment to preclude, eliminate or reverse cancer phenotypes and treatment resistance.

Anticancer drug FL118 formulation for treatment of human cancer

Described herein, are the chemical synthesis, matter of compositions, formulation, function, methods and uses of the FL118 platform Positions 7 and/or 9-derived analogues for treating cancer or other human diseases. Compounds derived from chemical modifications of the FL118 platform are employed alone or in combination with other anti-cancer agents to preclude, eliminate or reverse cancer phenotypes. This invention intends to realize unique personalized cancer treatment (personalized precision medicine) through application of a series of structural relevant individual FL118 platform-derived analogues, which target multiple cellular human disease-relevant proteins and their signaling pathways.

Matter of composition, synthesis, formulation and application of FL118 platform positions 7 and 9-derived analogues for treatment of human disease

Described herein, are FL118 core structure platform compounds, matter of compositions, formulation, methods and uses for treating cancer or other human diseases. Chemical modifications of the FL118 structure are employed alone or in combination with other anti-cancer agents to preclude or reverse refractory cancer phenotypes and for unique personalized cancer treatment (personalized medicine or as Obama called precision medicine) through application of a series of structural relevant individual FL118 platform-derived analogues.

Use of the FL118 core chemical structure platform to generate FL118 derivatives for treatment of human disease

Described herein, are FL118 core structure platform compounds, matter of compositions, formulation, methods and uses for treating cancer or other human diseases. Chemical modifications of the FL118 structure are employed alone or in combination with other anti-cancer agents to preclude or reverse refractory cancer phenotypes and for unique personalized cancer treatment (personalized medicine or as Obama called precision medicine) through application of a series of structural relevant individual FL118 platform-derived analogs.

Use of the FL-one hundred eighteen core chemical structure platform to generate FL-one hundred eighteen derivatives for treatment of human disease

Provided are compositions, methods of making the compositions, and methods of using the compositions. The compositions can be provided as pharmaceutical preparations for use in disease treatment, such as cancer therapy. The compositions include novel pharmaceutical preparations which contain effective concentrations of a chemical compound. One compound used is 10H-1,3-Dioxolo[4,5-g]pyrano[3',4&#x2032;:6,7]indolizino[1,2-b]quinoline-8,11(7H,12H)-dione, 7-ethyl-7-hydroxy-, (S)-. The invention also provides methodologies for preparing pharmaceutical preparations for use in intravenous and oral pharmaceutical preparations that contain drug compounds that are difficult to dissolve in water.

Formulations of water-insoluble chemical compounds and methods of using a formulation of compound FL118 for cancer therapy

Provided are methods for determining whether an individual is a candidate to receive treatment with a DNA methylation inhibitor. The method can be performed a biological sample of cancerous tissue of the individual. Determining that PDEF expression is absent or low and survivin expression is present identifies the individual as a candidate to receive a treatment with a DNA methylation inhibitor. The method also includes communicating the result of identifying an individual as a candidate for receiving a DNA methylation inhibitor to a health care provider.

Methods for analysis of PDEF and survivin as interconnected cancer biomarkers and targets for personalized medicine

Disclosed are compounds having the formula: wherein Zis an alkylene moiety; Q is a carboxylic acid derivative; and Rand Rare the same or different and are selected from the group consisting of alkyl, aryl, alkylcarbonyl, arylcarbonyl, hydroxycarbonyl, and alkoxycarbonyl or Rand R, taken together with the nitrogen atom to which they are bound, form a ring. Also disclosed are compounds having the formula: wherein Zis an alkylene moiety; Q is a carboxylic acid derivative; and Ris selected from the group consisting of alkyl and aryl. The compounds can be used to modulate cell proliferation and/or apoptosis, for example, in the treatment of cancers and other proliferative diseases, disorders, and conditions.

Azepans and methods for making and using same

Provided are compositions and methods for identifying agents that can modulate expression of the human survivin gene. The compositions include eukaryotic cells that contain a human survivin promoter sequence operably linked to a reporter gene. The method comprises determining whether a test agent can modulate transcription from a human survivin promoter sequence by adding a test agent to eukaryotic containing a human survivin promoter sequence operably linked to a reporter gene, measuring expression of the reporter gene and comparing expression of the reporter gene from to a control, wherein an increase or decrease of expression of the reporter gene relative to the control is indicative that the test agent can modulate transcription from a human survivin promoter. The method also comprises the use of SPlucTg mice for preclinical drug identification, including testing of candidate drug toxicity and efficacy.

Growing community of inventors

Buffalo, NY, United States of America

Fengzhi Li